Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
EDITOR The point estimate and confidence intervals of the treatment
effect shown by Hellemons et al2 could be combined with
the estimated costs of both preventing and treating strokes. In this way a model of cost effectiveness related to different baseline risks
could be constructed. This, however, is rather different from the way
that Taylor and Ebrahim suggest using the cost ratio. It is indeed
unlikely from the trial data that anticoagulation is 15 times as
effective as aspirin, but this does not mean that anticoagulation must
prevent 15 times as many strokes to be cost effective.
Since the overall cost of treating patients with stroke is likely
to be higher than the cost of drugs for preventing stroke, a relatively
small benefit from anticoagulation might lead to an overall cost
benefit in comparison with aspirin. This will be increasingly likely as
the baseline risk of stroke increases.
As authors of other letters in the cluster have noted, the
confidence intervals of the relative risk found by Hellemons et al are
not tight enough to rule out a moderate beneficial effect of
anticoagulation in comparison with aspirin.3 Although cost should be considered in choosing between aspirin and anticoagulation for patients with atrial fibrillation (alongside individual patients' risks and preferences for treatment), it should not be used to demand
that the statistical difference between treatments matches the
differential costs of one part of the service provision.
The argument in the letter from Taylor and Ebrahim starts from
the premise that the cost of providing an anticoagulation service for
patients with atrial fibrillation is 15 times higher than that of
treating with aspirin.1 The inference that anticoagulation must be shown to be 15 times as effective as aspirin in the prevention of stroke is not correct because it ignores the costs of treating patients who develop strokes.
Manor View Practice, Bushey, Hertfordshire WD2 2NN
chriscates{at}emailmsn.com
| 1. | Taylor FC, Ebrahim S. Using anticoagulation or aspirin to prevent stroke. BMJ 2000; 320: 1010. (8 April.) |
| 2. |
Hellemons BSP, Langenberg M, Lodder J, Vermeer F, Schouten HJA, Lemmens T, et al.
Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin.
BMJ
1999;
319:
958-964 |
| 3. |
Correspondence. Using anticoagulation or aspirin to prevent stroke.
BMJ
2000;
320:
1008-1011 |
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.